<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00154089</url>
  </required_header>
  <id_info>
    <org_study_id>EM-1421 #201</org_study_id>
    <nct_id>NCT00154089</nct_id>
  </id_info>
  <brief_title>A Pilot Study of EM-1421 for the Treatment of Cervical Intraepithelial Neoplasia</brief_title>
  <official_title>A Pilot Translational Study of Tetra-O-Methyl Nordihydroguaiaretic Acid (EM-1421) for the Treatment of Cervical Intraepithelial Neoplasia Induced by Human Papilloma Virus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erimos Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Maryland, Baltimore County</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Planned Parenthood Delaware (Wilmington, DE)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Erimos Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine pilot safety and efficacy data for a
      topical formulation of EM-1421 applied to the cervix of patients with CIN 1, 2, or 3.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was an open-label, pilot Phase I/II dose evaluation and pharmacokinetic evaluation study
      to compare the safety and efficacy of terameprocol (45mg or 90mg/application)administered
      once per week for 3 weeks to the cervix uteri in patients with biopsy-proven CIN. Patients
      who met eligibility criteria visited the clinic weekly for terameprocol application. Patients
      kept a daily diary card record of genitourinary symptoms.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <primary_completion_date type="Actual">April 2006</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Cervical Intraepithelial Neoplasia</condition>
  <arm_group>
    <arm_group_label>EM-1421</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of EM-1421 intravaginally once per week for 3 weeks
Dose level of 45 mg/application (1% w/w) or 90 mg/application (2% w/w)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EM-1421</intervention_name>
    <description>EM-1421 administered intravaginally every 3 weeks as 45 mg (1% w/w) EM-1421 or 90 mg (2% w/w) EM-1421</description>
    <arm_group_label>EM-1421</arm_group_label>
    <other_name>Terameprocol</other_name>
    <other_name>M4N</other_name>
    <other_name>Tetra-O-Methyl Nordihydroguaiaretic Acid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older

          -  Negative pregnancy test

          -  Biopsy confirmed CIN 1, 2, or 3

        Exclusion Criteria:

          -  Pregnancy or breast feeding
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Maryland, Dept. of Family Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>February 20, 2016</last_update_submitted>
  <last_update_submitted_qc>February 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cervical intraepithelial neoplasia</keyword>
  <keyword>CIN</keyword>
  <keyword>HPV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Masoprocol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

